Antibiotic sensitivity testing

  (Redirected from Antibiotic susceptibility testing)

Antibiotic sensitivity testing or antibiotic susceptibility testing is the measurement of the susceptibility of bacteria to antibiotics. It is used because bacteria may have resistance to some antibiotics. Sensitivity testing results can allow a clinician to change the choice of antibiotics from empiric therapy, which is when an antibiotic is selected based on clinical suspicion about the site of an infection and common causative bacteria, to directed therapy, in which the choice of antibiotic is based on knowledge of the organism and its sensitivities.[1]

Example of antibiotic sensitivity testing. Thin paper discs containing an antibiotic have been placed on an agar plate growing bacteria. Bacteria are not able to grow around antibiotics to which they are sensitive. This is called "the zone of inhibition".

Sensitivity testing usually occurs in a medical laboratory, and may be based on culture methods that expose bacteria to antibiotics, or genetic methods that test to see if bacteria have genes that confer resistance. Culture methods often involve measuring the diameter of areas without bacterial growth, called zones of inhibition, around paper discs containing antibiotics on agar culture dishes that have been evenly inoculated with bacteria. The minimum inhibitory concentration, which is the lowest concentration of the antibiotic that stops the growth of bacteria, can be estimated from the size of the zone of inhibition.

Antibiotic susceptibility testing has occurred since the discovery of the beta-lactam antibiotic penicillin. Initial methods were phenotypic, and involved culture or dilution. The Etest, an antibiotic impregnated strip, has been available since the 1980s, and genetic methods such as polymerase chain reaction (PCR) testing have been available since the early 2000s. Research is ongoing into improving current methods by making them faster or more accurate, as well as developing new methods for testing, such as microfluidics.

UsesEdit

In clinical medicine, antibiotics are most frequently prescribed on the basis of a person's symptoms and medical guidelines. This method of antibiotic selection is called empiric therapy,[1] and it is based on knowledge about what bacteria cause an infection, and what antibiotics bacteria may be sensitive or resistant to in a geographical area.[1] For example, a simple urinary tract infection might be treated with trimethoprim/sulfamethoxazole.[2] This is because Escherichia coli is the most likely causative bacterium, and may be sensitive to that combination antibiotic.[2] However, bacteria can be resistant to several classes of antibiotics.[2] This resistance might be because a type of bacteria has intrinsic resistance to some antibiotics,[2] because of resistance following past exposure to antibiotics,[2] or because resistance may be transmitted from other sources such as plasmids.[3] Antibiotic sensitivity testing provides information about which antibiotics are more likely to be successful and should therefore be used to treat the infection.[1]

Antibiotic sensitivity testing is also conducted at a population level in some countries as a form of screening.[4] This is to assess the background rates of resistance to antibiotics (for example with methicillin-resistant Staphylococcus aureus), and may influence guidelines and public health measures.[4]

MethodsEdit

 
Example of an Etest, which uses a plastic strip impregnated with an antibiotic at a range of concentrations

Testing for antibiotic sensitivity usually occurs in a laboratory.[5] Once a bacterium has been identified following microbiological culture, antibiotics are selected for susceptibility testing.[6] Susceptibility testing methods are based on exposing bacteria to antibiotics and observing the response (phenotypic testing), or specific genetic tests (genetic testing).[7] Methods used may be qualitative, meaning a result indicates resistance is or is not present; or quantitative, using a minimum inhibitory concentration (MIC) to describe the concentration of antibiotic to which a bacterium is sensitive.[7]

There are nearly a dozen factors that can affect the results of antibiotic sensitivity testing, including failure of the instrument, temperature, moisture, and potency of the antimicrobial agent. Quality control (QC) testing helps to ensure the accuracy of test results; QC guidelines are available from the Clinical and Laboratory Standards Institute (CLSI).[8]

Phenotypic methodsEdit

Testing based on exposing bacteria to antibiotics uses agar plates or dilution in agar or broth.[9] The selection of antibiotics will depend on the organism grown, and the antibiotics that are available locally.[6] To ensure that the results are accurate, the concentration of bacteria that is added to the agar or broth (the inoculum) must be standardized. This is accomplished by comparing the turbidity of bacteria suspended in saline or broth to McFarland standards—solutions whose turbidity is equivalent to that of a suspension containing a given concentration of bacteria. Once an appropriate concentration has been reached, which can be determined by visual inspection or by photometry, the inoculum is added to the growth medium.[10][11]

The disc diffusion method involves selecting a strain of bacteria, placing it on an agar plate, and observing bacterial growth near antibiotic-impregnated discs.[12] This is also called the Kirby-Bauer method,[13] although modified methods are also used.[14] Small paper discs containing antibiotics are placed onto a plate upon which bacteria are growing. If the antibiotic inhibits microbial growth, a clear ring, or zone of inhibition, is seen around the disc. The bacteria are classified as sensitive, intermediate, or resistant to an antibiotic by comparing the diameter of the zone of inhibition to defined thresholds which correlate with MICs.[14][15] Mueller-Hinton agar is frequently used in this antibiotic susceptibility test.[14] Standards exist as to how the testing is performed, and how the test results are interpreted.[6] The CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) provide standards for the type and depth of agar, temperature of incubation, and method of analysing results.[10] Disc diffusion is considered the cheapest and most simple of the methods used to test for susceptibility, and is easily adapted to testing newly available antibiotics or formulations.[6] Some slow-growing and fastidious bacteria cannot be accurately tested by this method,[6] while others, such as Streptococcus species and Haemophilus influenzae, can be tested but require specialized growth media and incubation conditions.[16]

Gradient methods, such as Etest, use a plastic strip placed on agar.[6] A plastic strip impregnated with different concentrations of antibiotics is placed on a growth medium, and the growth medium is viewed after a period of incubation.[6] The minimum inhibitory concentration can be identified based on the intersection of the teardrop-shaped zone of inhibition with the marking on the strip.[6] Multiple strips for different antibiotics may be used.[6] This type of test is considered a diffusion test.[17]

In agar and broth dilution methods, bacteria are placed in multiple small tubes with different concentrations of antibiotics.[14] Whether a bacterium is sensitive or not is determined by visual inspection or automatic optical methods, after a period of incubation.[6] Broth dilution is considered the gold standard for phenotypic testing.[14] The lowest concentration of antibiotics that inhibits growth is considered the MIC.[6]

Matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF MS) is another method of phenotypic susceptibility testing.[7] This is a form of time-of-flight mass spectrometry, in which the molecules of a bacterium are subject to matrix-assisted laser desorption.[18] The ionised particles are then accelerated, and spectral peaks recorded, producing an expression profile, which is capable of differentiating specific bacterial strains after being compared to known profiles.[18] This includes, in the context of antibiotic susceptibility testing, strains such as beta-lactamase producing E coli.[9] MALDI-TOF is rapid and automated.[9] There are limitations to testing in this format however; results may not match the results of phenotypic testing,[9] and acquisition and maintenance is expensive.[19]

Automated systems exist that replicate manual processes, for example, by using pictures and software analysis to report the zone of inhibition in diffusion testing, or dispensing samples and determining results in dilutional testing.[14]

Genetic methodsEdit

Genetic testing, such as via polymerase chain reaction (PCR), DNA microarray, DNA chips, and loop-mediated isothermal amplification, may be used to detect whether bacteria possess genes which confer antibiotic resistance.[9][20] An example is the use of PCR to detect the mecA gene for beta-lactam resistant Staphylococcus aureus.[9] Other examples include assays for testing vancomycin resistance genes vanA and vanB in Enteroccocus species, and antibiotic resistance in Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli.[9] These tests have the benefit of being direct and rapid, as compared with observable methods,[9] and have a high likelihood of detecting a finding when there is one to detect.[21] However, whether resistance genes are detected does not always match the resistance profile seen with phenotypic method.[9] The tests are also expensive and require specifically trained personnel.[19]

Polymerase chain reaction is a method of identifying genes related to antibiotic susceptibility.[18] In the PCR process, a bacterium's genome is denatured. Primers specific to a sought-after gene are added to a solution containing the DNA, and a DNA polymerase is added alongside a mixture containing molecules that will be needed (for example, nucleotides and ions).[19] If the relevant gene is present, every time this process runs, the quantity of the target gene will be doubled.[19] After this process, the presence of the genes is demonstrated through a variety of methods including electrophoresis, southern blotting, and other DNA sequencing analysis methods.[19]

DNA microarrays and chips use the binding of complementary DNA to a target gene or nucleic acid sequence.[9] The benefit of this is that multiple genes can be assessed simultaneously.[9]

ReportingEdit

The results of the testing are reported as a table, sometimes called an antibiogram.[22] Bacteria might be marked as sensitive, resistant, or having intermediate resistance to an antibiotic.[5] Specific patterns of drug resistance or multi drug resistance may be noted, such as the presence of an extended-spectrum beta lactamase.[5]

The sensitive, resistant or intermediate resistance to antibiotics is reported based on the minimum inhibitory concentration. It is compared to known values for a given bacterium and antibiotic.[5] For example, the CLSI defines Streptococcus pneumoniae as sensitive to penicillin if MICs are ≤0.06 μg/ml, intermediate if MICs are 0.12 to 1 μg/ml, and resistant if MICs are ≥2 μg/ml.[23] Such information may be useful to the clinician, who can change the empiric treatment, to a tailored treatment that is directed only at the causative bacterium.[1][9] Sometimes, whether an antibiotic is marked as resistant is also based on bacterial characteristics that are associated with known methods of resistance such as the potential for beta-lactamase production.[5][24]

Clinical practiceEdit

 
Antibiotic resistance tests: Bacteria are streaked on dishes with white disks, each impregnated with a different antibiotic. Clear rings, such as those on the left, show that bacteria have not grown—indicating that these bacteria are not resistant. The bacteria on the right are fully resistant to all but two of the seven antibiotics tested.[25]

Ideal antibiotic therapy is based on determining the causal agent and its antibiotic sensitivity. Empiric treatment is often started before laboratory microbiological reports are available. This might be for common or minor infections based on clinical guidelines (such as community-acquired pneumonia), or due to the seriousness of an infection and the risk of treatment delay (such as sepsis or bacterial meningitis).[1] The effectiveness of individual antibiotics varies with the anatomical site of the infection, the ability of the antibiotic to reach the site of infection, and the ability of the bacteria to resist or inactivate the antibiotic.[26]

When specimens are taken, this is ideally before treatment is started.[1] A sample may be taken from the site of a suspected infection; such as a blood culture sample when bacteria are suspected to be present in the bloodstream (bacteraemia), a sputum sample in the case of a pneumonia, or a urine sample in the case of a urinary tract infection. Sometimes multiple samples may be taken if the source of an infection is not clear.[1] These samples are transferred to the microbiology laboratory where they are added to culture media where microscopy and sensitivity testing to any bacteria that grow will occur.[27][5]

When antibiotic sensitivity testing is reported, it will report the organisms present in the sample, and which antibiotics they are susceptible to.[5] Although antibiotic sensitivity testing is done in a laboratory (in vitro), the information provided about this is often clinically relevant to the antibiotics in a person (in vivo).[28] Sometimes, decision must be made for some bacteria as to whether they are the cause of an infection, or simply commensal bacteria or contaminants,[5] such as Staphylococcus epidermidis[29] and other opportunistic infections. Other considerations may influence the choice of antibiotics, including the need to penetrate through to an infected site (such as an abscess), or the suspicion that one or more causes of an infection were not detected in a sample.[1]

HistoryEdit

Since the discovery of the beta-lactam antibiotic penicillin, the rates of antimicrobial resistance have increased. Over time, methods for testing the sensitivity of bacteria to antibiotics have developed and changed.[19]

Alexander Fleming in the 1920s developed the first method of susceptibility testing. The "gutter method" that he developed was a diffusion method, involving an antibiotic that was diffused through a gutter made of agar.[19] In the 1940s, multiple investigators, including Pope, Foster and Woodruff, Vincent and Vincent used paper discs instead.[19] All these methods involve testing only susceptibility to penicillin.[19] The results were difficult to interpret and not reliable, because of inaccurate results that were not standardised between laboratories.[19]

Dilution has been used as a method to grow and identify bacteria since the 1870s, and as a method of testing the susceptibility of bacteria to antibiotics since 1929, also by Alexander Fleming.[19] The way of determining susceptibility changed from how turbid the solution was, to the pH (in 1942), to optical instruments.[19] The use of larger tube-based "macrodilution" testing has been superseded by smaller "microdilution" kits.[6]

In 1966, the World Health Organisation confirmed the Kirby-Bauer method as the standard method for susceptibility testing; it is simple, cost-effective and can test multiple antibiotics.[19]

The Etest was developed in 1980 by Bolmstrӧm and Eriksson, and MALDI-TOF developed in 2000s.[19] An array of automated systems has been developed since and after the 1980s.[19] PCR was the first genetic test available and first published as a method of detecting antibiotic susceptibility in 2001.[19]

Further researchEdit

Point-of-care testing is being developed to speed up the time for testing, and to help practitioners avoid prescribing unnecessary antibiotics in the style of precision medicine.[30] Traditional techniques typically take between 12 and 48 hours,[7] although it can take up to five days.[5] In contrast, rapid testing using molecular diagnostics is defined as "being feasible within an 8-h(our) working shift".[7] Progress has been slow due to a range of reasons including cost and regulation.[31]

Additional research is focused at the shortcomings of current testing methods. As well as the duration it takes to report phenotypic methods, they are laborious, have difficult portability and are difficult to use in resource-limited settings, and have a chance of cross-contamination.[19]

As of 2017, point-of-care resistance diagnostics were available for methicillin-resistant Staphylococcus aureus (MRSA), rifampin-resistant Mycobacterium tuberculosis (TB), and vancomycin-resistant enterococci (VRE) through GeneXpert by molecular diagnostics company Cepheid.[32]

Quantitative PCR, with the view of determining the percent of a detected bacteria that possesses a resistance gene, is being explored.[9] Whole genome sequencing of isolated bacteria is also being explored, and likely to become more available as costs decrease and speed increases over time.[9]

Additional methods explored include microfluidics, which uses a small amount of fluid and a variety of testing methods, such as optical, electrochemical, and magnetic.[9] Such assays do not require much fluid to be tested, are rapid and portable.[9]

The use of fluorescent dyes has been explored.[9] These involve labelled proteins targeted at biomarkers, nucleic acid sequences present within cells that are found when the bacterium is resistant to an antibiotic.[9] An isolate of bacteria is fixed in position and then dissolved. The isolate is then exposed to fluoresent dye, which will be luminescent when viewed.[9]

Improvements to existing platforms are also being explored, including improvements in imaging systems that are able to more rapidly identify the MIC in phenotypic samples; or the use of bioluminescent enzymes that reveal bacterial growth to make changes more easily visible.[19]

See alsoEdit

BibliographyEdit

  • Burnett D (2005). The science of laboratory diagnosis. Chichester, West Sussex, England Hoboken, NJ: Wiley. ISBN 978-0-470-85912-4. OCLC 56650888.
  • Mahon C, Lehman D, Manuselis G (2018). Textbook of Diagnostic Microbiology (6 ed.). Elsevier Health Sciences. ISBN 978-0-323-48212-7.

ReferencesEdit

  1. ^ a b c d e f g h i Leekha S, Terrell CL, Edson RS (February 2011). "General principles of antimicrobial therapy". Mayo Clinic Proceedings. 86 (2): 156–67. doi:10.4065/mcp.2010.0639. PMC 3031442. PMID 21282489. Once microbiology results have helped to identify the etiologic pathogen and/or antimicrobial susceptibility data are available, every attempt should be made to narrow the antibiotic spectrum. This is a critically important component of antibiotic therapy because it can reduce cost and toxicity and prevent the emergence of antimicrobial resistance in the community
  2. ^ a b c d e Kang CI, Kim J, Park DW, Kim BN, Ha US, Lee SJ, et al. (March 2018). "Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections". Infection & Chemotherapy. 50 (1): 67–100. doi:10.3947/ic.2018.50.1.67. PMC 5895837. PMID 29637759.
  3. ^ Partridge SR, Kwong SM, Firth N, Jensen SO (October 2018). "Mobile Genetic Elements Associated with Antimicrobial Resistance". Clinical Microbiology Reviews. 31 (4). doi:10.1128/CMR.00088-17. PMC 6148190. PMID 30068738.
  4. ^ a b Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA (May 2013). Weinstein RA (ed.). "The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia". Clinical Infectious Diseases. 56 (9): 1310–8. doi:10.1093/cid/cit020. PMID 23334810.
  5. ^ a b c d e f g h i Giuliano C, Patel CR, Kale-Pradhan PB (April 2019). "A Guide to Bacterial Culture Identification And Results Interpretation". P & T. 44 (4): 192–200. PMC 6428495. PMID 30930604.
  6. ^ a b c d e f g h i j k l Jorgensen JH, Ferraro MJ (December 2009). "Antimicrobial susceptibility testing: a review of general principles and contemporary practices". Clinical Infectious Diseases. 49 (11): 1749–55. doi:10.1086/647952. PMID 19857164.
  7. ^ a b c d e van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, Mohess A, et al. (January 2019). "Developmental roadmap for antimicrobial susceptibility testing systems". Nature Reviews. Microbiology. 17 (1): 51–62. doi:10.1038/s41579-018-0098-9. PMC 7138758. PMID 30333569.
  8. ^ Mahon 2018, p. 95.
  9. ^ a b c d e f g h i j k l m n o p q r s Pulido MR, García-Quintanilla M, Martín-Peña R, Cisneros JM, McConnell MJ (December 2013). "Progress on the development of rapid methods for antimicrobial susceptibility testing". The Journal of Antimicrobial Chemotherapy. 68 (12): 2710–7. doi:10.1093/jac/dkt253. PMID 23818283.
  10. ^ a b Hombach, Michael; Maurer, Florian P.; Pfiffner, Tamara; Böttger, Erik C.; Furrer, Reinhard (2015-12-01). "Standardization of Operator-Dependent Variables Affecting Precision and Accuracy of the Disk Diffusion Method for Antibiotic Susceptibility Testing". Journal of Clinical Microbiology. 53 (12): 3864–3869. doi:10.1128/JCM.02351-15. ISSN 0095-1137. PMC 4652116. PMID 26468500.
  11. ^ Mahon 2018, p. 273.
  12. ^ Syal K, Mo M, Yu H, Iriya R, Jing W, Guodong S, et al. (2017). "Current and emerging techniques for antibiotic susceptibility tests". Theranostics. 7 (7): 1795–1805. doi:10.7150/thno.19217. PMC 5479269. PMID 28638468.
  13. ^ "WHO | World Health Organization". WHO. Retrieved 2020-09-03. The most common methods utilized are the disk diffusion susceptibility test method (also known as Kirby-Bauer)
  14. ^ a b c d e f Jorgensen, James H.; Turnidge, John D. (2015). "71. Susceptibility Test Methods: Dilution and Disk Diffusion Methods". In Jorgensen, James H; Carroll, Karen C; Funke, Guido; Pfaller, Michael A; Landry, Marie Louise; Richter, Sandra S; Warnock, David W (eds.). Manual of Clinical Microbiology (11th ed.). pp. 1253–1273. doi:10.1128/9781555817381. ISBN 9781683672807.
  15. ^ Mahon 2018, pp. 278–9.
  16. ^ Mahon 2018, pp. 279–82.
  17. ^ Burnett 2005, p. 169.
  18. ^ a b c Bauer KA, Perez KK, Forrest GN, Goff DA (October 2014). "Review of rapid diagnostic tests used by antimicrobial stewardship programs". Clinical Infectious Diseases. 59 Suppl 3 (suppl_3): S134-45. doi:10.1093/cid/ciu547. PMID 25261540.
  19. ^ a b c d e f g h i j k l m n o p q r Khan ZA, Siddiqui MF, Park S (May 2019). "Current and Emerging Methods of Antibiotic Susceptibility Testing". Diagnostics. 9 (2): 49. doi:10.3390/diagnostics9020049. PMC 6627445. PMID 31058811.
  20. ^ Poirel L, Jayol A, Nordmann P (April 2017). "Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes". Clinical Microbiology Reviews. 30 (2): 557–596. doi:10.1128/CMR.00064-16. PMC 5355641. PMID 28275006.
  21. ^ Arena, Fabio; Viaggi, Bruno; Galli, Luisa; Rossolini, Gian Maria (October 2015). "Antibiotic Susceptibility Testing: Present and Future". The Pediatric Infectious Disease Journal. 34 (10): 1128–1130. doi:10.1097/INF.0000000000000844. PMID 26186102.
  22. ^ "Medical Definition of ANTIBIOGRAM". www.merriam-webster.com. Retrieved 2020-07-05.
  23. ^ Weinstein, Melvin P.; Klugman, Keith P.; Jones, Ronald N. (June 2009). "Rationale for Revised Penicillin Susceptibility Breakpoints versus Streptococcus pneumoniae: Coping with Antimicrobial Susceptibility in an Era of Resistance". Clinical Infectious Diseases. 48 (11): 1596–1600. doi:10.1086/598975. ISSN 1058-4838. PMID 19400744.
  24. ^ Winstanley T, Courvalin P (July 2011). "Expert systems in clinical microbiology". Clinical Microbiology Reviews. 24 (3): 515–56. doi:10.1128/CMR.00061-10. PMC 3131062. PMID 21734247.
  25. ^ Kirby-Bauer Disk Diffusion Susceptibility Test Protocol Archived 26 June 2011 at the Wayback Machine, Jan Hudzicki, ASM
  26. ^ Burnett 2005, p. 167.
  27. ^ Burnett 2005, pp. 135–144.
  28. ^ Burnett 2005, p. 168.
  29. ^ Becker K, Heilmann C, Peters G (October 2014). "Coagulase-negative staphylococci". Clinical Microbiology Reviews. 27 (4): 870–926. doi:10.1128/CMR.00109-13. PMC 4187637. PMID 25278577.
  30. ^ "Diagnostics Are Helping Counter Antimicrobial Resistance, But More Work Is Needed". MDDI Online. 2018-11-20. Retrieved 2018-12-02.
  31. ^ "Progress on antibiotic resistance". Nature. 562 (7727): 307. October 2018. Bibcode:2018Natur.562Q.307.. doi:10.1038/d41586-018-07031-7. PMID 30333595.
  32. ^ McAdams D (January 2017). "Resistance diagnosis and the changing epidemiology of antibiotic resistance". Annals of the New York Academy of Sciences. 1388 (1): 5–17. Bibcode:2017NYASA1388....5M. doi:10.1111/nyas.13300. PMID 28134444.

External linksEdit